354 related articles for article (PubMed ID: 26137402)
1. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
3. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
4. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
5. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
6. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response.
Weir GM; Hrytsenko O; Stanford MM; Berinstein NL; Karkada M; Liwski RS; Mansour M
Oncoimmunology; 2014; 3(8):e953407. PubMed ID: 25960932
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
8. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
9. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
11. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
Doloff JC; Waxman DJ
Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
[TBL] [Abstract][Full Text] [Related]
12. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
Shiraga E; Barichello JM; Ishida T; Kiwada H
Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
15. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
Vergato C; Doshi KA; Roblyer D; Waxman DJ
Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
17. Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway.
Zhong H; Lai Y; Zhang R; Daoud A; Feng Q; Zhou J; Shang J
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023984
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer.
Noguchi M; Moriya F; Koga N; Matsueda S; Sasada T; Yamada A; Kakuma T; Itoh K
Cancer Immunol Immunother; 2016 Feb; 65(2):151-60. PubMed ID: 26728480
[TBL] [Abstract][Full Text] [Related]
19. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.
Alizadeh D; Zhang L; Brown CE; Farrukh O; Jensen MC; Badie B
Clin Cancer Res; 2010 Jul; 16(13):3399-408. PubMed ID: 20570924
[TBL] [Abstract][Full Text] [Related]
20. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
